Freddy A. Jimenez

Freddy A. Jimenez, listed as senior executive, appears in our data through filings on Celldex Therapeutics, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 11 August 2021 to 4 December 2025, the count stands at 6 filings.

The open-market side counts 1 purchase for €17k alongside 2 sales for €111k. The net balance comes to €94k on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 3 option exercises. Since January 2025: no purchases and 2 sales on the market.

The record was last updated on 8 December 2025 with an open-market sale (€104k) in Celldex Therapeutics, Inc. The last purchase on record was published on 13 August 2021, which is 1,892 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.